SiMa.ai and HTEC Strengthen Strategic Partnership to Advance Premium ML System-on-Chip Solutions
HTEC, a global digital engineering services firm, is pleased to announce a partnership extension with SiMa.ai, the software-centric, embedded edge machine learning system-on-chip (MLSoC) company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250220864540/en/
HTEC announces partnership extension with SiMa.ai, an embedded edge machine learning system-on-chip company. (Graphic: Business Wire)
During a successful five-year collaboration, SiMa.ai and HTEC built an ML compiler, system drivers, and other complex AI-powered software tools to support SiMa.ai’s edge AI platform. SiMa.ai also leveraged HTEC’s AI- and ML-driven engineering and chip optimization expertise to enhance its purpose-built MLSoC™.
Now, HTEC will support SiMa.ai’s strategic initiatives and help streamline the delivery of SiMa.ai solutions built on its cutting-edge ONE Platform for Edge AI, further enhancing the company’s hardware and software.
“Collaborating with SiMa.ai five years ago on software for their machine learning SoC was a challenge we couldn’t turn down! SiMa.ai created unique and highly performant hardware and recognized that they needed an equally unique, highly efficient software stack. We are glad to have contributed to their success story, and we look forward to supporting these new initiatives.” — Petar Jovanović, Director of Technology, Embedded, HTEC.
“As a leader in embedded edge solutions, we needed a strong partner to help deliver a complex software stack for our MLSoC. HTEC’s AI and ML engineering expertise and experience in the embedded edge market make them a true strategic partner, and we look forward to creating more innovative solutions together.” — Ashok Sudarsanam, Associate Vice President, MLA Software, SiMa.ai.
Visit HTEC at Embedded World for an exclusive look at GenAI applications powered by SiMa.ai’s Modalix platform.
About SiMa.ai:
SiMa.ai is the software-centric, embedded edge machine learning system-on-chip (MLSoC) company. SiMa.ai delivers ONE Platform for Edge AI that flexibly adjusts to any framework, network, model, sensor, or modality. With SiMa.ai, customers unlock new paths to revenue and significant cost savings to innovate at the edge across industrial manufacturing, retail, aerospace, defense, agriculture, and healthcare. SiMa.ai was founded in 2018 and is backed by Fidelity Management & Research Company, Maverick Capital, Point72, MSD Partners, VentureTech Alliance, and more.
About HTEC:
HTEC Group Inc. is a global AI-first provider of strategic services, software design, and engineering expertise, specializing in Telco, Financial Services, MedTech, Automotive, Advanced Technologies, and Enterprise Software & Platforms. HTEC has a proven track record of helping Fortune 500 and hyper-growth companies solve complex engineering challenges, drive efficiency, reduce costs, and accelerate time to market. HTEC prides itself on attracting top talent and has strategically chosen the locations of its 20+ excellence centers to enable this.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220864540/en/
Contacts
HTEC Media Relations: media@htecgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 10:15:00 EEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 10:00:00 EEST | Press release
Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vice President, Skechers Technical Performance Division. “An evolution of our legacy in running, Skechers AERO was d
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 10:00:00 EEST | Press release
Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP and Optical Transport, Mobile Networks, Mobile Services, and Data Centres. “Network X is more than a conference—it
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 08:00:00 EEST | Press release
4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P004. “Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis,” said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. “Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. B
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 20:06:00 EEST | Press release
Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The company’s global headquarters includes WPC certified test equipment and state-of-the-art test labs dedicated to full product lifecycle validatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom